Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Terns Pharmaceuticals (TERN) Operating Income (2020 - 2022)

Terns Pharmaceuticals' Operating Income history spans 3 years, with the latest figure at -$16.8 million for Q4 2022.

  • For Q4 2022, Operating Income fell 21.26% year-over-year to -$16.8 million; the TTM value through Dec 2022 reached -$62.0 million, down 24.41%, while the annual FY2025 figure was -$110.1 million, 8.1% down from the prior year.
  • Operating Income reached -$16.8 million in Q4 2022 per TERN's latest filing, up from -$17.3 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of -$8.7 million in Q3 2020 to a low of -$17.3 million in Q3 2022.
  • Average Operating Income over 3 years is -$12.4 million, with a median of -$12.6 million recorded in 2021.
  • Peak YoY movement for Operating Income: crashed 58.28% in 2021, then decreased 3.98% in 2022.
  • A 3-year view of Operating Income shows it stood at -$8.8 million in 2020, then plummeted by 58.28% to -$13.9 million in 2021, then dropped by 21.26% to -$16.8 million in 2022.
  • Per Business Quant, the three most recent readings for TERN's Operating Income are -$16.8 million (Q4 2022), -$17.3 million (Q3 2022), and -$14.1 million (Q2 2022).